Cancer Detection 

u  Earlier detection of the critical signs of breast cancer development is key to successful treatment
u  Mammograms tend to detect cancerous lesions that are well along in the development cycle

u  According to the American Cancer Society, one in eight women in the United States will be diagnosed with breast cancer in her lifetime and early detection is vital for survival

u  An estimated 75 million mammograms are performed annually world wide

u  The Company’s technology is applicable to detection of other forms of cancer

u The Company’s technology has significant future possible applications such as:

rheumatoid arthritis, cardiovascular disease, adult blindness, and many other diseases plus the effectiveness monitoring of anti-angiogenic drug therapies

Value Proposition 

u  Advanced low-cost, non-invasive imaging technology detecting angiogenesis (creation of new blood vessels) associated with cancer development

q       Painless one-minute process, with results immediately available

q       Equipment 60-75% less expensive than digital mammography

q       High sensitivity and specificity rates thereby reducing false positive test results

q       False positive test results from mammography create need for 3 million expensive ($2,500-$5,000) biopsies per year, of which 20% are positive and 80% are negative.

u  Helps to discriminate between malignant and benign lesions – thus reducing unnecessary biopsies

u  Designed to identify breast cancer at its earliest stage of development (potentially years)

q       May allow intervention prior to cancer developing into advanced stages 

Market Opportunity           

u  $4+ billion for augmentation of the mammographic equipment market

q       35,000+ installations; $140k projected price per device  

u  500 million cases of angiogenesis-based diseases per year in Western Nations 

q       At $100 per scan, represents substantial opportunity to practitioners; an exciting new opportunity for equipment providers 

Commercializing patented, low cost, non-invasive scanning system that detects the vascular elements fundamental to the development of breast cancer, with 98% negative predictive value

" The Company's technology may be able to detect cancer years earlier than other available methods; poised to compete with mammography as a screening tool within three years with the potential to play a major role in a $4 billion plus market

" FDA approval: Four of five steps completed. Final step expected to commence in early 2003, complete in mid-2004. Over 1,400 patients successfully scanned to date. CE mark is in place to ship to EEU countries and elsewhere

" Potential equipment market exceeds $4 billion (assuming 1 scanning system at each of 35,000 existing mammogram installations)

" Growing backlog of international orders

" Estimated 75 million mammograms performed annually worldwide

" Company sells scanning device, software, maintenance, upgrades, creating installed base and growing high margin annuity stream

" Retail price of DOBI scanner is $140,000, compared to $350,000 to $500,000 for digital mammographic systems